Month: September 2021

Total revenue of $11.6 million, including net gain on investments of $11.5 million for the three months ended July 31, 2021 Net income for the three months ended July 31, 2021 was $10.9 million or $0.08 per basic shareAs at July 31, 2021, Aberdeen’s shareholders’ equity and net asset value (NAV) were $51.9 million, or $0.38 per basic share. On a quarter-over-quarter basis, Aberdeen’s shareholders’ equity has increased by $10.9 million, representing an approximate 27% increase. Given the nature of Aberdeen’s operations, there is currently no difference between “shareholder equity” and “net asset value” for AberdeenInvestments in clean energy and zero-carbon technologies drove significant value during the first half of 2021, accounting for an approximately $11.9 million gain on investment, affirming the focus...

PETAH-TIKVA, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) — Global-e Online Ltd. (Nasdaq: GLBE) (the “Company” or “Global-e”), the world’s leading platform to enable and accelerate global, direct-to-consumer cross-border e-commerce, today announced the pricing of the previously announced underwritten secondary offering by certain of its shareholders (the “Selling Shareholders”) of 12,000,000 of the Company’s ordinary shares at a price to the public of $64.00 per share (the “Offering”). The Offering is expected to close on or about September 14, 2021, subject to the satisfaction of customary closing conditions. In addition, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,800,000 ordinary shares at the public offering price, less underwriting discounts. The Selling Shareholders...

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd Annual Global Investment Conference Mon., Sept. 13, 2021Fireside chat available on-demand beginning at 7:00 a.m. ET Cell & Gene Therapy World Asia 2021 conferenceWed., Sept. 15, 2021Presentation Time: 4:45 PM (SGT)Keynote Presentation Topic: VB-111: Transformative Gene therapy with the Potential to Change the Treatment Paradigm for Solid Tumors Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Wed., Sept. 22, 2021Fireside chat at 1:15 PM – 1:55 PM (ET). Webcasts will be available via the Events and Presentations section of the Company’s Investor Relations page. About VBL TherapeuticsVascular Biogenics Ltd., operating...

Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico Infant Bacterial Therapeutics AB today announces that the Mexican Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III. The ambition for IBP-9414 is to become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications are currently pending in additional future key markets including the US and Europe. This patent increases...

SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of a public offering of 20,000,000 shares of Maravai’s Class A common stock by certain selling stockholders that was previously announced, at a public offering price of $50.00 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of Maravai’s Class A common stock. The offering is expected to close on September 14, 2021, subject to customary closing conditions. Maravai will not receive any proceeds from the sale of shares by the selling stockholders. Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC...

Bank of Åland PlcOther information disclosed according to the rules of the ExchangeSeptember 10, 2021, 13:00 EET Approval of the prospectus by the Finnish Financial Supervision Authority and notification of an application for the admission of a security to trading in a regulated market The Finnish Financial Supervision Authority has today approved a prospectus prepared by Ålandsbanken Abp (“Ålandsbanken”) as the initial issuer and Borgo AB (“Borgo”) as the subsequent issuer. Ålandsbanken has under the prospectus issued a SEK 5,500,000,000 Covered Bonds due 2026 (ISIN:SE0013360419) (the “Notes”) with terms and conditions allowing Notes to be transferred to Borgo at a later stage subject to the approval of Ålandsbanken and Borgo. Ålandsbanken has filed an application to Nasdaq Helsinki Ltd for the admission of the Notes to trading in a...

Kari Williams, Former Vice President of Marketing at Rolls Royce, is the second major addition to Optilan’s Executive Management Team this year. Optilan is a global services provider for Critical Network Infrastructure, Energy, Pipeline Integrity, Rail, Telecommunications, and Renewables NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) — Dark Pulse, Inc. (OTC Markets: DPLS) (“DarkPulse” and the “Company”), a technology company focused on the manufacture, sale, installation, and monitoring of laser sensing systems based on its patented BOTDA dark-pulse sensor technology (the “DarkPulse Technology”) which provides a data stream of critical metrics for assessing the health and security of infrastructure, today announced Kari Williams, Former Rolls Royce VP, has been appointed to Optilan’s Executive Team as Sales & Marketing Director. Ms....

Registration of share capital reduction and disbursements On 10 September 2021, the share capital reduction of AS Trigon Property Development (registry code: 10106774; hereinafter the “Company”) was registered in the Estonian Commercial Register according to the resolutions adopted by the annual general meeting of shareholders on 4 June 2021. The share capital was reduced by the reduction of the book value of the shares by 0.411 Euros per share, as a result of which the book value of one share was reduced from 0.511 Euros to 0.10 Euros per share. The number of shares of the company remained the same (4 499 061) and the book value of shares was reduced proportionately to the reduction of the share capital. Based on the foregoing, the share capital of the Company decreased by 1,849,114.07 Euros, from 2,299,020.17 Euros to 449,906.10 Euros. The...